Walleye Capital LLC Invests $3.20 Million in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Walleye Capital LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,121,738 shares of the company’s stock, valued at approximately $3,197,000. Walleye Capital LLC owned approximately 0.75% of Xeris Biopharma as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of XERS. Vanguard Group Inc. raised its holdings in Xeris Biopharma by 7.3% in the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock valued at $16,810,000 after acquiring an additional 519,897 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Xeris Biopharma by 188.5% in the 3rd quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock valued at $172,000 after acquiring an additional 39,335 shares during the last quarter. Simplicity Wealth LLC acquired a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $27,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Xeris Biopharma during the third quarter worth approximately $35,000. Finally, Renaissance Technologies LLC boosted its holdings in Xeris Biopharma by 33.9% in the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after purchasing an additional 342,300 shares in the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Monday, November 11th. HC Wainwright boosted their price target on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Stock Up 3.0 %

XERS opened at $3.38 on Tuesday. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.69 and a 52 week high of $3.64. The business’s 50 day moving average is $3.07 and its two-hundred day moving average is $2.64. The firm has a market cap of $503.89 million, a price-to-earnings ratio of -7.51 and a beta of 2.65.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.